Ann: Viraleze shows antiviral efficacy in COVID-19 patients, page-66

like I said, if they had already cleared the virus before end date and were not reporting data on the questionnaire because of this, then unfortunately there is no complete graph to produce for that cohort. They tried to recruit more participants to give the study more power overall and make for an overall more reliable result but clearly not enough. Don’t you think it strange that viraleze would have a greater effect for older less healthy individuals. That doesn’t make sense to me. I’m betting the treatment is particularly effective for the younger cohorts but cannot be reported for the various reasons I’ve suggested 100 times. Remember the trial only ran for 7 days I think with one endpoint date day 7. Perhaps they should have included in the questionnaire more endpoint dates so statical significance could be reported at an endpoint date day 2, day 3, day4 etc. It’s my opinion. That’s what I’ll continue to argue until proven wrong. If they don’t have the statistics to report for that group they cannot make things up.